These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21397856)

  • 1. URI is an oncogene amplified in ovarian cancer cells and is required for their survival.
    Theurillat JP; Metzler SC; Henzi N; Djouder N; Helbling M; Zimmermann AK; Jacob F; Soltermann A; Caduff R; Heinzelmann-Schwarz V; Moch H; Krek W
    Cancer Cell; 2011 Mar; 19(3):317-32. PubMed ID: 21397856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S6K1-mediated disassembly of mitochondrial URI/PP1gamma complexes activates a negative feedback program that counters S6K1 survival signaling.
    Djouder N; Metzler SC; Schmidt A; Wirbelauer C; Gstaiger M; Aebersold R; Hess D; Krek W
    Mol Cell; 2007 Oct; 28(1):28-40. PubMed ID: 17936702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
    Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
    Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor promoting properties of the ETS protein MEF in ovarian cancer.
    Yao JJ; Liu Y; Lacorazza HD; Soslow RA; Scandura JM; Nimer SD; Hedvat CV
    Oncogene; 2007 Jun; 26(27):4032-7. PubMed ID: 17213815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
    Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
    Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.
    Noske A; Brandt S; Valtcheva N; Wagner U; Zhong Q; Bellini E; Fink D; Obermann EC; Moch H; Wild PJ
    Oncotarget; 2017 Feb; 8(9):14794-14805. PubMed ID: 27582547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling.
    Yalcin A; Clem B; Makoni S; Clem A; Nelson K; Thornburg J; Siow D; Lane AN; Brock SE; Goswami U; Eaton JW; Telang S; Chesney J
    Oncogene; 2010 Jan; 29(1):139-49. PubMed ID: 19855431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer.
    Popadiuk CM; Xiong J; Wells MG; Andrews PG; Dankwa K; Hirasawa K; Lake BB; Kao KR
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2216-23. PubMed ID: 16609037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
    Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
    Etemadmoghadam D; Au-Yeung G; Wall M; Mitchell C; Kansara M; Loehrer E; Batzios C; George J; Ftouni S; Weir BA; Carter S; Gresshoff I; Mileshkin L; Rischin D; Hahn WC; Waring PM; Getz G; Cullinane C; Campbell LJ; Bowtell DD
    Clin Cancer Res; 2013 Nov; 19(21):5960-71. PubMed ID: 24004674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
    Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of adaptor protein Crk in malignant feature of human ovarian cancer cell line MCAS.
    Linghu H; Tsuda M; Makino Y; Sakai M; Watanabe T; Ichihara S; Sawa H; Nagashima K; Mochizuki N; Tanaka S
    Oncogene; 2006 Jun; 25(25):3547-56. PubMed ID: 16491127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological role and prognostic significance of NAC1 in ovarian cancer.
    Nakayama K; Rahman MT; Rahman M; Yeasmin S; Ishikawa M; Katagiri A; Iida K; Nakayama N; Miyazaki K
    Gynecol Oncol; 2010 Dec; 119(3):469-78. PubMed ID: 20869761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.
    Jang GY; Jeon JH; Cho SY; Shin DM; Kim CW; Jeong EM; Bae HC; Kim TW; Lee SH; Choi Y; Lee DS; Park SC; Kim IG
    Oncogene; 2010 Jan; 29(3):356-67. PubMed ID: 19838207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.
    Itamochi H; Oishi T; Shimada M; Sato S; Uegaki K; Naniwa J; Sato S; Nonaka M; Terakawa N; Kigawa J; Harada T
    Clin Cancer Res; 2011 Jul; 17(14):4742-50. PubMed ID: 21610153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.
    Kanou T; Oneyama C; Kawahara K; Okimura A; Ohta M; Ikeda N; Shintani Y; Okumura M; Okada M
    Mol Cancer Res; 2011 Jan; 9(1):103-14. PubMed ID: 21156787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth.
    Zhang L; Yang N; Huang J; Buckanovich RJ; Liang S; Barchetti A; Vezzani C; O'Brien-Jenkins A; Wang J; Ward MR; Courreges MC; Fracchioli S; Medina A; Katsaros D; Weber BL; Coukos G
    Cancer Res; 2005 Feb; 65(3):925-32. PubMed ID: 15705892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of CD9 in ovarian cancer is related to the induction of TNF-α gene expression and constitutive NF-κB activation.
    Hwang JR; Jo K; Lee Y; Sung BJ; Park YW; Lee JH
    Carcinogenesis; 2012 Jan; 33(1):77-83. PubMed ID: 22095071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L).
    Frankel A; Rosen K; Filmus J; Kerbel RS
    Cancer Res; 2001 Jun; 61(12):4837-41. PubMed ID: 11406560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma.
    Nucera C; Eeckhoute J; Finn S; Carroll JS; Ligon AH; Priolo C; Fadda G; Toner M; Sheils O; Attard M; Pontecorvi A; Nose V; Loda M; Brown M
    Clin Cancer Res; 2009 Jun; 15(11):3680-9. PubMed ID: 19470727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.